Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.
about
Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Octreotide LAR and Prednisone ...... ymic Tumors: A Phase II Study.
@ast
Octreotide LAR and Prednisone ...... ymic Tumors: A Phase II Study.
@en
type
label
Octreotide LAR and Prednisone ...... ymic Tumors: A Phase II Study.
@ast
Octreotide LAR and Prednisone ...... ymic Tumors: A Phase II Study.
@en
prefLabel
Octreotide LAR and Prednisone ...... ymic Tumors: A Phase II Study.
@ast
Octreotide LAR and Prednisone ...... ymic Tumors: A Phase II Study.
@en
P2093
P2860
P1433
P1476
Octreotide LAR and Prednisone ...... ymic Tumors: A Phase II Study.
@en
P2093
Alexander Marx
Berthold Schalke
Christoph May
Claudia Baierlein
Hans-Stefan Hofmann
Julia Kleylein-Sohn
Jörg Marienhagen
Karsten Wiebe
Lukas Kirzinger
Michael Ried
P2860
P304
P356
10.1371/JOURNAL.PONE.0168215
P407
P577
2016-12-16T00:00:00Z